Lyra Cash And Short Term Investments vs Accounts Payable Analysis

LYRA Stock

USD 0.21 0.02 10.53%

Lyra Therapeutics financial indicator trend analysis is infinitely more than just investigating Lyra Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lyra Therapeutics is a good investment. Please check the relationship between Lyra Therapeutics Cash And Short Term Investments and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.

Cash And Short Term Investments vs Accounts Payable

Cash And Short Term Investments vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lyra Therapeutics Cash And Short Term Investments account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.

The correlation between Lyra Therapeutics' Cash And Short Term Investments and Accounts Payable is 0.77. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Lyra Therapeutics, assuming nothing else is changed. The correlation between historical values of Lyra Therapeutics' Cash And Short Term Investments and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Lyra Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Cash And Short Term Investments i.e., Lyra Therapeutics' Cash And Short Term Investments and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Lyra Therapeutics balance sheet. This account contains Lyra Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lyra Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Accounts Payable

An accounting item on the balance sheet that represents Lyra Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lyra Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Lyra Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lyra Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.At present, Lyra Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 73.5 M, whereas Selling General Administrative is forecasted to decline to about 12.6 M.

	2021	2022	2023	2024 (projected)
Interest Income	102K	1.0M	4.1M	4.3M
Net Interest Income	102K	1.0M	4.1M	4.3M

Interest Income Net Interest Income

Lyra Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.77	0.83	0.84	0.87	0.92	0.73	0.09	-0.9	0.81	0.4	0.76	0.8	0.9	0.99	-0.52	0.82	-0.65	0.89	0.66	0.93	-0.61	0.84	0.73	0.99	0.96
Other Current Liab	0.77		0.7	0.64	0.75	0.73	0.37	0.0	-0.72	0.72	0.25	0.43	0.87	0.71	0.82	-0.26	0.61	-0.5	0.7	0.66	0.71	-0.46	0.64	0.36	0.82	0.8
Total Current Liabilities	0.83	0.7		0.84	0.77	0.84	0.7	0.17	-0.89	1.0	0.26	0.73	0.77	0.77	0.79	-0.49	0.77	-0.76	0.87	0.81	0.88	-0.71	0.84	0.69	0.79	0.69
Total Stockholder Equity	0.84	0.64	0.84		0.81	0.93	0.71	0.02	-0.87	0.82	0.51	0.75	0.72	0.9	0.84	-0.56	0.79	-0.94	0.94	0.74	0.97	-0.93	1.0	0.71	0.84	0.79
Other Liab	0.87	0.75	0.77	0.81		0.83	0.87	0.47	-0.97	0.77	0.13	0.91	0.87	0.97	0.84	-0.79	0.98	-0.6	0.81	0.5	0.78	-0.57	0.81	0.87	0.84	0.8
Net Tangible Assets	0.92	0.73	0.84	0.93	0.83		0.73	-0.07	-0.9	0.82	0.63	0.76	0.67	0.9	0.93	-0.6	0.79	-0.78	0.99	0.84	0.96	-0.76	0.93	0.73	0.93	0.9
Property Plant And Equipment Net	0.73	0.37	0.7	0.71	0.87	0.73		0.55	-0.9	0.67	0.13	1.0	0.58	0.86	0.66	-0.94	0.95	-0.51	0.74	0.4	0.67	-0.48	0.71	1.0	0.66	0.61
Net Debt	0.09	0.0	0.17	0.02	0.47	-0.07	0.55		-0.37	0.17	-0.74	0.55	0.38	0.3	-0.02	-0.6	0.55	0.1	-0.05	-0.35	-0.08	0.12	0.02	0.56	-0.03	-0.07
Retained Earnings	-0.9	-0.72	-0.89	-0.87	-0.97	-0.9	-0.9	-0.37		-0.88	-0.24	-0.93	-0.83	-0.95	-0.87	0.77	-0.97	0.69	-0.9	-0.65	-0.87	0.65	-0.87	-0.9	-0.87	-0.8
Accounts Payable	0.81	0.72	1.0	0.82	0.77	0.82	0.67	0.17	-0.88		0.24	0.71	0.78	0.75	0.77	-0.47	0.76	-0.75	0.86	0.82	0.86	-0.7	0.82	0.67	0.78	0.67
Cash	0.4	0.25	0.26	0.51	0.13	0.63	0.13	-0.74	-0.24	0.24		0.13	-0.06	0.31	0.49	-0.1	0.09	-0.49	0.62	0.69	0.56	-0.51	0.51	0.13	0.49	0.51
Non Current Assets Total	0.76	0.43	0.73	0.75	0.91	0.76	1.0	0.55	-0.93	0.71	0.13		0.64	0.89	0.7	-0.93	0.97	-0.55	0.77	0.43	0.7	-0.52	0.75	1.0	0.7	0.64
Non Currrent Assets Other	0.8	0.87	0.77	0.72	0.87	0.67	0.58	0.38	-0.83	0.78	-0.06	0.64		0.82	0.78	-0.42	0.79	-0.59	0.65	0.45	0.73	-0.55	0.72	0.57	0.79	0.74
Other Assets	0.9	0.71	0.77	0.9	0.97	0.9	0.86	0.3	-0.95	0.75	0.31	0.89	0.82		0.89	-0.76	0.94	-0.72	0.88	0.56	0.87	-0.7	0.9	0.85	0.89	0.86
Cash And Short Term Investments	0.99	0.82	0.79	0.84	0.84	0.93	0.66	-0.02	-0.87	0.77	0.49	0.7	0.78	0.89		-0.47	0.77	-0.65	0.9	0.7	0.93	-0.61	0.84	0.66	1.0	0.99
Net Receivables	-0.52	-0.26	-0.49	-0.56	-0.79	-0.6	-0.94	-0.6	0.77	-0.47	-0.1	-0.93	-0.42	-0.76	-0.47		-0.88	0.36	-0.61	-0.27	-0.47	0.34	-0.56	-0.94	-0.47	-0.44
Common Stock Shares Outstanding	0.82	0.61	0.77	0.79	0.98	0.79	0.95	0.55	-0.97	0.76	0.09	0.97	0.79	0.94	0.77	-0.88		-0.58	0.79	0.46	0.75	-0.55	0.79	0.95	0.77	0.71
Non Current Liabilities Total	-0.65	-0.5	-0.76	-0.94	-0.6	-0.78	-0.51	0.1	0.69	-0.75	-0.49	-0.55	-0.59	-0.72	-0.65	0.36	-0.58		-0.82	-0.72	-0.88	1.0	-0.94	-0.51	-0.65	-0.58
Capital Surpluse	0.89	0.7	0.87	0.94	0.81	0.99	0.74	-0.05	-0.9	0.86	0.62	0.77	0.65	0.88	0.9	-0.61	0.79	-0.82		0.87	0.96	-0.79	0.94	0.74	0.9	0.85
Other Current Assets	0.66	0.66	0.81	0.74	0.5	0.84	0.4	-0.35	-0.65	0.82	0.69	0.43	0.45	0.56	0.7	-0.27	0.46	-0.72	0.87		0.8	-0.68	0.74	0.39	0.7	0.63
Other Stockholder Equity	0.93	0.71	0.88	0.97	0.78	0.96	0.67	-0.08	-0.87	0.86	0.56	0.7	0.73	0.87	0.93	-0.47	0.75	-0.88	0.96	0.8		-0.85	0.97	0.66	0.92	0.88
Total Liab	-0.61	-0.46	-0.71	-0.93	-0.57	-0.76	-0.48	0.12	0.65	-0.7	-0.51	-0.52	-0.55	-0.7	-0.61	0.34	-0.55	1.0	-0.79	-0.68	-0.85		-0.93	-0.48	-0.61	-0.55
Net Invested Capital	0.84	0.64	0.84	1.0	0.81	0.93	0.71	0.02	-0.87	0.82	0.51	0.75	0.72	0.9	0.84	-0.56	0.79	-0.94	0.94	0.74	0.97	-0.93		0.71	0.84	0.79
Property Plant And Equipment Gross	0.73	0.36	0.69	0.71	0.87	0.73	1.0	0.56	-0.9	0.67	0.13	1.0	0.57	0.85	0.66	-0.94	0.95	-0.51	0.74	0.39	0.66	-0.48	0.71		0.65	0.6
Total Current Assets	0.99	0.82	0.79	0.84	0.84	0.93	0.66	-0.03	-0.87	0.78	0.49	0.7	0.79	0.89	1.0	-0.47	0.77	-0.65	0.9	0.7	0.92	-0.61	0.84	0.65		0.99
Net Working Capital	0.96	0.8	0.69	0.79	0.8	0.9	0.61	-0.07	-0.8	0.67	0.51	0.64	0.74	0.86	0.99	-0.44	0.71	-0.58	0.85	0.63	0.88	-0.55	0.79	0.6	0.99

Click cells to compare fundamentals

Lyra Therapeutics Account Relationship Matchups

Lyra Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.0M	80.8M	54.9M	110.0M	142.6M	78.6M
Other Current Liab	110K	2.0M	3.2M	9.0M	3.9M	3.6M
Total Current Liabilities	5.2M	4.9M	18.2M	14.5M	19.6M	11.8M
Total Stockholder Equity	7.3M	74.5M	34.3M	80.8M	89.4M	93.9M
Net Tangible Assets	(123.3M)	74.5M	34.3M	80.8M	92.9M	97.5M
Net Debt	(6.5M)	(72.2M)	(44.3M)	(30.3M)	4.5M	4.8M
Retained Earnings	(127.8M)	(149.9M)	(193.4M)	(248.7M)	(311.4M)	(295.8M)
Accounts Payable	1.1M	922K	3.1M	2.6M	3.1M	2.1M
Cash	9.8M	74.6M	45.7M	32.6M	22.4M	38.3M
Non Current Assets Total	4.8M	4.9M	6.9M	9.1M	37.8M	39.7M
Non Currrent Assets Other	1.1M	118K	762K	3.3M	2.5M	1.5M
Other Assets	1.4M	2.7M	1.1M	4.7M	5.4M	5.6M
Cash And Short Term Investments	9.8M	74.6M	45.7M	97.9M	102.8M	65.0M
Common Stock Shares Outstanding	12.9M	8.6M	13.0M	30.2M	49.8M	52.3M
Liabilities And Stockholders Equity	15.0M	80.8M	54.9M	110.0M	142.6M	78.6M
Non Current Liabilities Total	2.4M	1.5M	2.3M	14.7M	33.6M	24.7M
Capital Lease Obligations	3.3M	2.4M	1.5M	2.2M	26.9M	28.2M
Other Current Assets	311K	2.6M	4.3M	2.9M	2.1M	2.4M
Other Stockholder Equity	4.4M	305.2M	227.7M	329.4M	400.7M	209.8M
Total Liab	7.6M	6.3M	20.6M	29.2M	53.2M	33.2M
Net Invested Capital	7.3M	74.5M	34.3M	80.8M	89.4M	93.9M
Total Current Assets	10.1M	75.9M	47.9M	100.8M	104.8M	66.8M
Net Working Capital	4.9M	71.0M	29.7M	86.4M	85.2M	55.0M
Property Plant Equipment	3.4M	2.2M	5.9M	4.5M	5.1M	3.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:

How To Invest In Lyra

Details

Is Lyra Stock a good investment?

Details

What is Lyra Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.49)

Revenue Per Share

0.023

Quarterly Revenue Growth

(0.64)

Return On Assets

(0.42)

Return On Equity

(1.86)

The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lyra Cash And Short Term Investments vs Accounts Payable Analysis

Cash And Short Term Investments vs Accounts Payable

Cash And Short Term Investments vs Accounts Payable Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Accounts Payable

Lyra Therapeutics fundamental ratios Correlations

Lyra Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lyra Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accounts Payable	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Non Current Assets Total
Total Current Assets	+ 1.0	Cash And Short Term Investments

Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Liab
Other Assets	- 0.95	Retained Earnings
Net Invested Capital	- 0.94	Non Current Liabilities Total
Property Plant And Equipment Gross	- 0.94	Net Receivables
Net Receivables	- 0.94	Property Plant And Equipment Net